
NATURE . COM {
}
Title:
A phase II trial with rosiglitazone in liposarcoma patients | British Journal of Cancer
Description:
Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4 mg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2 – 16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Science
- Education
- Health & Fitness
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌆 Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$536,300 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $357,503 to $983,134.
Keywords {🔍}
patients, liposarcoma, pparγ, treatment, pubmed, article, google, scholar, cancer, cas, nature, rosiglitazone, clinical, liposarcomas, human, expression, patient, gene, differentiation, molecular, peroxisome, proliferatoractivated, receptor, tumour, cells, study, months, cell, tontonoz, gamma, analysis, data, troglitazone, spiegelman, leuven, level, fletcher, cookies, content, trial, genes, biological, adipsin, protein, myxoid, fusion, activation, performed, probe, privacy,
Topics {✒️}
nature portfolio privacy policy peroxisome proliferator-activated receptor-γ peroxisome-proliferator activated receptor-gamma advertising nature 363 nature soft-tissue sarcoma—gold standard social media peroxisome proliferator-activated receptors author information authors 0/ reprints lipid-activated transcription factor pax8-ppargamma1 fusion oncogene author correspondence tls-chop fusion protein ews-chop fusion transcript ultrasound-guided needle biopsy full size image permissions myxoid/round cell subtypes inhibit tumour growth myxoid/round cell liposarcomas high affinity ligand soft tissue simulators privacy 14 october 2003 rna-binding protein primary tumour sample dei tos utilising standard procedures explore content tissue-specific regulator journals search log solid tumor differentiation human colon cancer metastastic colon cancer van den bh human myxoid liposarcoma round cell liposarcoma cellular proliferation rates european economic area personal data meis-kindblom giant marker chromosomes chromosomal region 12q spring-driven device quantify mrna levels glyceraldehyde-3-phosphate dehydrogenase g-banded chromosomes
Schema {🗺️}
WebPage:
mainEntity:
headline:A phase II trial with rosiglitazone in liposarcoma patients
description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
datePublished:2003-10-14T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1409
pageEnd:1412
sameAs:https://doi.org/10.1038/sj.bjc.6601306
keywords:
liposarcoma
rosiglitazone
PPARγ
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:A phase II trial with rosiglitazone in liposarcoma patients
description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
datePublished:2003-10-14T00:00:00Z
dateModified:2011-11-16T00:00:00Z
pageStart:1409
pageEnd:1412
sameAs:https://doi.org/10.1038/sj.bjc.6601306
keywords:
liposarcoma
rosiglitazone
PPARγ
Biomedicine
general
Cancer Research
Epidemiology
Molecular Medicine
Oncology
Drug Resistance
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
isPartOf:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:British Journal of Cancer
issn:
1532-1827
0007-0920
volumeNumber:89
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:G Debrock
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
email:[email protected]
name:V Vanhentenrijk
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:R Sciot
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:M Debiec-Rychter
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:R Oyen
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
name:A Van Oosterom
affiliation:
name:University Hospital Gasthuisberg, Universiteit Leuven
address:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
External Links {🔗}(83)
- Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11751490
- What's http://scholar.google.com/scholar_lookup?&title=Prognostic%20impact%20of%20p53%20status%2C%20TLS-CHOP%20fusion%20transcript%20structure%2C%20and%20histological%20grade%20in%20myxoid%20liposarcoma%3A%20a%20molecular%20and%20clinicopathologic%20study%20of%2082%20cases&journal=Clin%20Cancer%20Res&volume=7&pages=3977-3987&publication_year=2001&author=Antonescu%2CCR&author=Tschernyavsky%2CSJ&author=Decuseara%2CR&author=Leung%2CDH&author=Woodruff%2CJM&author=Brennan%2CMF&author=Bridge%2CJA&author=Neff%2CJR&author=Goldblum%2CJR&author=Ladanyi%2CM's gross income?
- Financial intake of https://doi.org/10.1016%2FS0024-3205%2802%2901510-2
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12269390?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Apoptosis%20induced%20by%20activation%20of%20peroxisome-proliferator%20activated%20receptor-gamma%20is%20associated%20with%20Bcl-2%20and%20NF-kappaB%20in%20human%20colon%20cancer&journal=Life%20Sci&doi=10.1016%2FS0024-3205%2802%2901510-2&volume=70&pages=2631-2646&publication_year=2002&author=Chen%2CGG&author=Lee%2CJF&author=Wang%2CSH&author=Chan%2CUP&author=Ip%2CPC&author=Lau%2CWY?
- What's the profit of https://doi.org/10.1038%2F363640a0?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8510758 each month?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Fusion%20of%20CHOP%20to%20a%20novel%20RNA-binding%20protein%20in%20human%20myxoid%20liposarcoma&journal=Nature&doi=10.1038%2F363640a0&volume=363&pages=640-644&publication_year=1993&author=Crozat%2CA&author=Aman%2CP&author=Mandahl%2CN&author=Ron%2CD
- How much profit does https://doi.org/10.1053%2Fadpa.2000.8133 make?
- How much does http://scholar.google.com/scholar_lookup?&title=Liposarcoma%3A%20new%20entities%20and%20evolving%20concepts&journal=Ann%20Design%20Pathol&doi=10.1053%2Fadpa.2000.8133&volume=4&pages=252-266&publication_year=2000&author=Dei%20Tos%2CAP earn?
- Profit of https://doi.org/10.1073%2Fpnas.96.7.3951
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10097144 make?
- What are the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22401?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Induction%20of%20solid%20tumor%20differentiation%20by%20the%20peroxisome%20proliferator-activated%20receptor-gamma%20ligand%20troglitazone%20in%20patients%20with%20liposarcoma&journal=Proc%20Natl%20Acad%20Sci%20USA&doi=10.1073%2Fpnas.96.7.3951&volume=96&pages=3951-3956&publication_year=1999&author=Demetri%2CGD&author=Fletcher%2CCD&author=Mueller%2CE&author=Sarraf%2CP&author=Naujoks%2CR&author=Campbell%2CN&author=Spiegelman%2CBM&author=Singer%2CS have monthly?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10954962's gross income?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Rosiglitazone&journal=Int%20J%20Clin%20Pract&volume=54&pages=333-337&publication_year=2000&author=Goldstein%2CBJ?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11431375's total income per month
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Mutational%20analysis%20of%20the%20peroxisome%20proliferator-activated%20receptor%20gamma%20gene%20in%20human%20malignancies&journal=Cancer%20Res&volume=61&pages=5307-5310&publication_year=2001&author=Ikezoe%2CT&author=Miller%2CCW&author=Kawano%2CS&author=Heaney%2CA&author=Williamson%2CEA&author=Hisatake%2CJ&author=Green%2CE&author=Hofmann%2CW&author=Taguchi%2CH&author=Koeffler%2CHP
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7805034 rake in every month?
- How much money does http://scholar.google.com/scholar_lookup?&title=Translocation%20t%2812%3B16%29%28q13%3Bp11%29%20in%20myxoid%20liposarcoma%20and%20round%20cell%20liposarcoma%3A%20molecular%20and%20cytogenetic%20analysis&journal=Cancer%20Res&volume=55&pages=24-27&publication_year=1995&author=Knight%2CJC&author=Renwick%2CPJ&author=Cin%2CPD&author=Van%20den%2CBH&author=Fletcher%2CCD make?
- How much profit does https://doi.org/10.1126%2Fscience.289.5483.1357 generate?
- How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10958784 have monthly?
- Income figures for http://scholar.google.com/scholar_lookup?&title=PAX8-PPARgamma1%20fusion%20oncogene%20in%20human%20thyroid%20carcinoma%20%5Bcorrected%5D&journal=Science&doi=10.1126%2Fscience.289.5483.1357&volume=289&pages=1357-1360&publication_year=2000&author=Kroll%2CTG&author=Sarraf%2CP&author=Pecciarini%2CL&author=Chen%2CCJ&author=Mueller%2CE&author=Spiegelman%2CBM&author=Fletcher%2CJA
- How much does https://doi.org/10.1097%2F00130404-200209000-00010 make?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12416897 each month?
- See how much http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20troglitazone%2C%20an%20activator%20of%20the%20PPARgamma%20receptor%2C%20in%20patients%20with%20chemotherapy-resistant%20metastatic%20colorectal%20cancer&journal=Cancer%20J&doi=10.1097%2F00130404-200209000-00010&volume=8&pages=395-399&publication_year=2002&author=Kulke%2CMH&author=Demetri%2CGD&author=Sharpless%2CNE&author=Ryan%2CDP&author=Shivdasani%2CR&author=Clark%2CJS&author=Spiegelman%2CBM&author=Kim%2CH&author=Mayer%2CRJ&author=Fuchs%2CCS makes per month
- What's the monthly money flow for https://doi.org/10.1074%2Fjbc.270.22.12953?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7768881
- http://scholar.google.com/scholar_lookup?&title=An%20antidiabetic%20thiazolidinedione%20is%20a%20high%20affinity%20ligand%20for%20peroxisome%20proliferator-activated%20receptor%20gamma%20%28PPAR%20gamma%29&journal=J%20Biol%20Chem&doi=10.1074%2Fjbc.270.22.12953&volume=270&pages=12953-12956&publication_year=1995&author=Lehmann%2CJM&author=Moore%2CLB&author=Smith-Oliver%2CTA&author=Wilkison%2CWO&author=Willson%2CTM&author=Kliewer%2CSA income
- What is the earnings of https://link.springer.com/doi/10.1007/s004280100423?
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11561754?
- How much does http://scholar.google.com/scholar_lookup?&title=Cytogenetic%20and%20molecular%20genetic%20analyses%20of%20liposarcoma%20and%20its%20soft%20tissue%20simulators%3A%20recognition%20of%20new%20variants%20and%20differential%20diagnosis&journal=Virchows%20Arch&doi=10.1007%2Fs004280100423&volume=439&pages=141-151&publication_year=2001&author=Meis-Kindblom%2CJM&author=Sjogren%2CH&author=Kindblom%2CLG&author=Peydro-Mellquist%2CA&author=Roijer%2CE&author=Aman%2CP&author=Stenman%2CG net monthly?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=ISCN.%20An%20International%20System%20for%20Human%20Genetic%20Nomenclature&publication_year=1995&author=Mitelman%2CF have monthly?
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11507074
- How much does http://scholar.google.com/scholar_lookup?&title=Anticancer%20effects%20of%20thiazolidinediones%20are%20independent%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20mediated%20by%20inhibition%20of%20translation%20initiation&journal=Cancer%20Res&volume=61&pages=6213-6218&publication_year=2001&author=Palakurthi%2CSS&author=Aktas%2CH&author=Grubissich%2CLM&author=Mortensen%2CRM&author=Halperin%2CJA pull in monthly?
- What is the monthly revenue of https://doi.org/10.1172%2FJCI0215634?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12370270 generate monthly?
- What's the financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151148?
- How much profit does http://scholar.google.com/scholar_lookup?&title=PPARgamma%20ligands%20inhibit%20primary%20tumor%20growth%20and%20metastasis%20by%20inhibiting%20angiogenesis&journal=J%20Clin%20Invest&doi=10.1172%2FJCI0215634&volume=110&pages=923-932&publication_year=2002&author=Panigrahy%2CD&author=Singer%2CS&author=Shen%2CLQ&author=Butterfield%2CCE&author=Freedman%2CDA&author=Chen%2CEJ&author=Moses%2CMA&author=Kilroy%2CS&author=Duensing%2CS&author=Fletcher%2CC&author=Fletcher%2CJA&author=Hlatky%2CL&author=Hahnfeldt%2CP&author=Folkman%2CJ&author=Kaipainen%2CA generate?
- How much does https://doi.org/10.1016%2FS1097-2765%2801%2980012-5 pull in?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10394368 gross monthly?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Loss-of-function%20mutations%20in%20PPAR%20gamma%20associated%20with%20human%20colon%20cancer&journal=Mol%20Cell&doi=10.1016%2FS1097-2765%2801%2980012-5&volume=3&pages=799-804&publication_year=1999&author=Sarraf%2CP&author=Mueller%2CE&author=Smith%2CWM&author=Wright%2CHM&author=Kum%2CJB&author=Aaltonen%2CLA&author=de%20la%2CCA&author=Spiegelman%2CBM&author=Eng%2CC earns monthly
- https://doi.org/10.1128%2FMCB.15.1.351 income
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7799943
- How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC231968 have monthly?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=PPAR%20gamma%202%20regulates%20adipose%20expression%20of%20the%20phosphoenolpyruvate%20carboxykinase%20gene&journal=Mol%20Cell%20Biol&doi=10.1128%2FMCB.15.1.351&volume=15&pages=351-357&publication_year=1995&author=Tontonoz%2CP&author=Hu%2CE&author=Devine%2CJ&author=Beale%2CEG&author=Spiegelman%2CBM is on a monthly basis
- Financial intake of https://doi.org/10.1101%2Fgad.8.10.1224
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7926726 make?
- How much profit does http://scholar.google.com/scholar_lookup?&title=mPPAR%20gamma%202%3A%20tissue-specific%20regulator%20of%20an%20adipocyte%20enhancer&journal=Genes%20Dev&doi=10.1101%2Fgad.8.10.1224&volume=8&pages=1224-1234&publication_year=1994&author=Tontonoz%2CP&author=Hu%2CE&author=Graves%2CRA&author=Budavari%2CAI&author=Spiegelman%2CBM generate?
- How much income does https://doi.org/10.1016%2F0092-8674%2894%2990006-X have?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8001151 make?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Stimulation%20of%20adipogenesis%20in%20fibroblasts%20by%20PPAR%20gamma%202%2C%20a%20lipid-activated%20transcription%20factor&journal=Cell&doi=10.1016%2F0092-8674%2894%2990006-X&volume=79&pages=1147-1156&publication_year=1994&author=Tontonoz%2CP&author=Hu%2CE&author=Spiegelman%2CBM generate?
- Find out how much https://doi.org/10.1073%2Fpnas.94.1.237 earns monthly
- What is the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8990192?
- How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC19300 make?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Terminal%20differentiation%20of%20human%20liposarcoma%20cells%20induced%20by%20ligands%20for%20peroxisome%20proliferator-activated%20receptor%20gamma%20and%20the%20retinoid%20X%20receptor&journal=Proc%20Natl%20Acad%20Sci%20USA&doi=10.1073%2Fpnas.94.1.237&volume=94&pages=237-241&publication_year=1997&author=Tontonoz%2CP&author=Singer%2CS&author=Forman%2CBM&author=Sarraf%2CP&author=Fletcher%2CJA&author=Fletcher%2CCD&author=Brun%2CRP&author=Mueller%2CE&author=Altiok%2CS&author=Oppenheim%2CH&author=Evans%2CRM&author=Spiegelman%2CBM earns monthly
- How much revenue does https://doi.org/10.1016%2FS0140-6736%2898%2910364-1 bring in?
- How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10408502 have monthly?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Medical%20significance%20of%20peroxisome%20proliferator-activated%20receptors&journal=Lancet&doi=10.1016%2FS0140-6736%2898%2910364-1&volume=354&pages=141-148&publication_year=1999&author=Vamecq%2CJ&author=Latruffe%2CN
- Get to know what's the income of https://citation-needed.springer.com/v2/references/10.1038/sj.bjc.6601306?format=refman&flavour=references
- Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=G%20Debrock
- What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22G%20Debrock%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=V%20Vanhentenrijk?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22V%20Vanhentenrijk%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R%20Sciot
- What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R%20Sciot%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20Debiec-Rychter?
- What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20Debiec-Rychter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=R%20Oyen
- What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22R%20Oyen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
- What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A%20Van%20Oosterom?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A%20Van%20Oosterom%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
- Earnings of https://s100.copyright.com/AppDispatchServlet?title=A%20phase%20II%20trial%20with%20rosiglitazone%20in%20liposarcoma%20patients&author=G%20Debrock%20et%20al&contentID=10.1038%2Fsj.bjc.6601306©right=The%20Author%28s%29&publication=0007-0920&publicationDate=2003-10-14&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-SA
- What are the total earnings of https://citation-needed.springer.com/v2/references/10.1038/sj.bjc.6601306?format=refman&flavour=citation?
- How much revenue does https://doi.org/10.1186/s12885-022-09379-6 bring in?
- How much does https://doi.org/10.1186/s12944-021-01593-8 pull in?
- How much income does https://doi.org/10.1186/s12885-016-2524-6 have?
- How much income does https://doi.org/10.1038/nrclinonc.2014.26 have?
- How much revenue does https://doi.org/10.1038/nrc3214 produce monthly?
- How much money does https://www.protocols.io/ generate?
- What's the revenue for https://www.natureindex.com/?
- How much income does http://www.naturechina.com have?
- https://www.natureasia.com/ja-jp income
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref